摘要
目的探究替罗非班对急性ST段抬高型心肌梗死介入治疗的临床应用价值。方法选取2019年5月至2020年9月本院收治并实施介入治疗的急性ST段抬高型心肌梗死患者106作为研究对象,随机分为对照组与研究组,每组53例。对照组采用常规经皮冠脉介入治疗(PCI),研究组在对照组基础上采用替罗非班药物治疗,比较两组TIMI分级、疗效、不良反应发生率及血小板聚集率。结果研究组血流3级占比高于对照组,差异有统计学意义(P<0.05)。研究组7 d ST段回落占比高于对照组,出血现象占比低于对照组,差异有统计学意义(P<0.05)。研究组不良反应发生率为7.55%,明显低于对照组的22.64%,差异有统计学意义(P<0.05)。干预前,两组血小板聚集率比较差异无统计学意义;干预24、48、72 h,研究组血小板聚集率均低于对照组,差异有统计学意义(P<0.05)。结论PCI干预下采用替罗非班药物治疗急性ST段抬高型心肌梗死患者效果显著,患者生理状态明显改善,值得临床推广应用。
Objective To explore the clinical application value of tirofiban in the interventional treatment of acute ST-segment elevation myocardial infarction.Methods 106 patients with acute ST-segment elevation myocardial infarction who received interventional therapy from May 2019 to September 2020 were selected as the research subjects,and they were randomly divided into control group and experimental group,with 53 cases in each group.The control group was treated with conventional percutaneous coronary intervention(PCI),and the experimental group was treated with tirofiban on the basis of the control group.The TIMI classification,clinical efficacy,incidence of adverse reactions and platelet aggregation rate were compared between the two groups.Results The proportion of blood flow grade 3 in the experimental group was higher than that in the control group,and the difference was statistically significant(P<0.05).The proportion of ST-segment fall in the experimental group was higher than that of the control group on the 7 th day,and the proportion of bleeding was lower than that of the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the experimental group was 7.55%,which was significantly lower than the 22.64%in the control group,and the difference was statistically significant(P<0.05).Before the intervention,there was no significant difference in the platelet aggregation rate between the two groups;the platelet aggregation rate of the experimental group was lower than that of the control group at 24,48,and 72 h after the intervention,and the difference was statistically significant(P<0.05).Conclusion The use of tirofiban under PCI intervention in the treatment of patients with acute ST-segment elevation myocardial infarction has significant effect,and the physiological status of the patients has been significantly improved,which is worthy of clinical application.
作者
高胜利
GAO Shengli(Department of Cardiology,Qufu People's Hospital,Shandong Province,Qufu,Shandong,273100,China)
出处
《当代医学》
2021年第35期56-58,共3页
Contemporary Medicine
关键词
替罗非班
急性ST段抬高型心肌梗死
介入治疗
临床研究
Tirofiban
Acute ST-segment elevation myocardial infarction
Interventional therapy
Clinical research
